|Bid||9.77 x 800|
|Ask||10.44 x 1200|
|Day's range||9.69 - 10.17|
|52-week range||7.34 - 58.37|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -122.22% and -41.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?